COVID-19 vaccines versus pediatric hospitalization

Vaccine effectiveness of BNT162b2 and CoronaVac against COVID-19-associated hospitalization and moderate-to-severe disease due to SARS-CoV-2 Omicron BA.2 is studied from the 1.36 million doses administered to 766,601 of 953,400 children aged 3–11 years and adolescents aged 12–18 years in Hong Kong a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa Duque, Jaime S., Leung, Daniel, Yip, Ka Man, Lee, Derek H.L., So, Hung-kwan, Wong, Wilfred H.S., Lau, Yu Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868379/
https://www.ncbi.nlm.nih.gov/pubmed/36801010
http://dx.doi.org/10.1016/j.xcrm.2023.100936
Descripción
Sumario:Vaccine effectiveness of BNT162b2 and CoronaVac against COVID-19-associated hospitalization and moderate-to-severe disease due to SARS-CoV-2 Omicron BA.2 is studied from the 1.36 million doses administered to 766,601 of 953,400 children aged 3–11 years and adolescents aged 12–18 years in Hong Kong as of April 2022. These vaccines confer substantial protection.

Ejemplares similares